Journals / Tüberküloz ve Toraks / 2010 / Cilt: 58 - Sayı: 4

The influence of community-acquired pneumonia to the clinical course in COPD cases admitted to intensive care unit with acute respiratory failure

Yoğun bakım ünitesine akut solunum yetmezliği ile kabul edilen KOAH olgularında pnömoni varlığının klinik seyre etkisi

Pages
408–417
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mortality was found 3 times higher (26.7%) than overall mortality (8.1%) in patients with IMV.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study the influence of community-acquired pneumonia to the clinical course in 173 COPD patients admitted to ICU with acute respiratory failure (ARF) was evaluated.
📊
Key Findings & Data:In prospective descriptive study, patients with pneumonia at admission to ICU were grouped as Group 1, others Group 2.
💡
Conclusion & Impact:Mortality was found 3 times higher (26.7%) than overall mortality (8.1%) in patients with IMV.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study the influence of community-acquired pneumonia to the clinical course in 173 COPD patients admitted to ICU with acute respiratory failure (ARF) was evaluated. In prospective descriptive study, patients with pneumonia at admission to ICU were grouped as Group 1, others Group 2. The demographics, Acute Physiology Assessment and Chronic Health Evaluation (APACHE) II scores, body mass index (BMI), comorbidities, steroid use, admission arterial blood gases (ABG), leucocyte and CRP, utilization and duration of non-invasive and invasive mechanical ventilation (NIMV and IMV), development of ventilator associated pneumonia (VAP) and septic shock, length of stay (LOS) in ICU and mortality of groups were recorded and compared. No differences were found between demographics, but leucocyte and CRP levels were determined higher in Group 1(p= 005, 0.001). NIMV, IMV ratio and IMV days are similar (respectively p= 0.419, 0.170, 0.459); NIMV was applied longer in Group 2 (p= 0.019). 4 (17.6%) patients in group 1 and 7 (6.3%) patients in Group 2 were switched to IMV(p= 0.083) due to NIMV failure.While VAP was detected in 8 (17.7%) cases of intubated 45 (26%) patients, rate of VAP was similar in both groups (p= 0.657). 2 (6.7%) patients in Group 1 and 12 (8.3%) patients in Group 2 died and no difference was found in terms of LOS in ICU. Mortality was found 3 times higher (26.7%) than overall mortality (8.1%) in patients with IMV. Mortality risk factors are higher CRP levels (p< 0.016, OR: 1.01 CI 95%: 1.00-1.02), NIMV application determined to reduce the mortality. In conclusions, the presence of pneumonia, on admission to ICU in COPD patients with ARF, didn t influence IMV duration, LOS and mortality in ICU. Although mortality can be higher in COPD patients with high CRP levels, but NIMV is thought to be a mortality reducing treatment approach.

Özet

Bu çalışmada akut solunum yetmezliği (ASY) ile yoğun bakım ünitemize (YBÜ) kabul edilen 173 kronik obstrüktif akciğer hastalığı (KOAH) olgusunda, eşlik eden toplum kökenli pnömoninin (TKP) klinik seyre etkisi değerlendirildi. İleriye dönük tanımlayıcı çalışmada; YBÜye girişte pnömonisi olan olgular grup 1 (n= 30), olmayanlar ise grup 2 (n= 143) olarak sınıflandırıldı. Grupların demografik özellikleri, Acute Physiology Assessment and Chronic Health Evaluation (APACHE) II skorları, beden kitle indeksleri (BKİ), komorbiditeleri, akut atak nedeniyle steroid kullanım süreleri, giriş arter kan gazı (AKG) bulguları, lökosit, C-reaktif protein (CRP) değerleri, invaziv ve noninvaziv mekanik ventilasyon (İMV ve NİMV) gereksinimleri ve süreleri, ventilatör ilişkili pnömoni (VİP) ve septik şok gelişmesi, YBÜ kalış süreleri ve mortaliteleri kayıt edilip karşılaştırıldı. Grupların demografik ve klinik özellikleri arasında farklılık bulunmazken; lökosit ve CRP değerleri Grup 1de anlamlı yüksek bulundu (sırasıyla p= 0.005, p= 0.001). NİMV, İMV uygulama oranı ve İMV süresi benzer (sırasıyla p= 0.419, 0.170, 0.459) olan gruplardan Grup 2ye daha uzun süre NİMV uygulandı (p= 0.019). Grup 1de 4 (%17.6), grup 2de 7 (%6.3) olguda NİMV başarısızlığı nedeniyle İMVye geçildi (p= 0.083). Entübe edilen 45 (%26) hastanın 8 (%17.7)inde VİP gelişirken, VİP oranı gruplarda benzerdi (p= 0.657). Grupların YBÜde kalış süresi benzer iken (p= 0.343), Grup 1de 2 (%6.7), Grup 2de 12 (%8.3) olgu öldü (p= 1.000). İMV uygulanan olgularda mortalite %26.7 ile genel mortaliteden (%8.1) yaklaşık 3 kat yüksek bulundu. Yüksek CRP değeri, mortalite için risk faktörü iken (p= 0.016, OR: 1.01 CI %95: 1.00- 1.02), NİMV uygulamasının ise mortaliteyi azalttığı bulundu (p = 0.022, OR: 0.033 CI %95: 0.00-0.61). Sonuç olarak çalışmamızda, YBÜye girişte pnömoni varlığının, ASY olan KOAH hastalarında, İMV, YBÜ de kalış süresini ve mortaliteyi etkilemediği gösterildi. Yüksek CRP, genel olarak KOAH hastalarında mortalite için risk faktörü iken; NİMV, mortalite azaltıcı bir tedavi yöntemi olarak düşünülebilir.

🔖

Cite This Article

YALÇINSOY, M., GÜNGÖR, G., SALTÜRK, C., KARAKURT, Z., ACARTÜRK, E., YAZICIOĞLU, Ö. M., BAŞBUĞ, Y. (2022). The influence of community-acquired pneumonia to the clinical course in COPD cases admitted to intensive care unit with acute respiratory failure. Tüberküloz ve Toraks, Cilt: 58 - Sayı: 4, 408–417. https://ajindex.com/articles/618807

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Patil S, Krishnan J, Lechtzin N, et al. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. /2003; 163: 1180-6
  2. Groenewegen KH, Schols AMWJ, Wouters E. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459-67
  3. Standarts for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society Statement. Am J Respir Crit Care Med 1995; 152: 77-120
  4. Khilnani GC, Banga A, Sharma SK. Predictors of mortality of patients with acute respiratory failure secondary to chronic obstructive pulmonary disease admitted to an intensive care unit: a one year study. BMC Pulm Med 2004; 4: 12
  5. Özlü T, Bülbül Y, Özsu S. Ulusal verilerle toplumda geli- şen pnömoniler. Tuberk Toraks 2007; 55: 191-212
  6. De Celis R, Torres A, Zalacain R, et al. Metodos de diagnistico y tratimiento de la neumonia adquirida en la comunidad en Espana: Estudio NACE (Diagnostic methods and treatment of community acquired pneumonia in Spain: NACE study). Med Clin (Barc) 2002; 119: 321-36
  7. Almirall J, Mesalles E, Klamgurg J, et al. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995; 107: 511-6
  8. Vallés J, Pobo A, García-Esquirol O, et al. Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset Intensive Care Med 2007; 33: 1363-8
  9. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27: 1210-6
  10. Torres A, Dorca J, Zalacain J, et al. Community acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996; 154: 1456-61
  11. Ruiz de Ona JM, Gomez Fernandez M, Celdran J,PuenteMaestu L. Neumonia en el paciente con enfermedad pulmonar obstructiva cronica. Niveles de gravedad y clases de riesgo[Pneumonia in the patient with chronic obstructive pulmonary disease. Levels of severity and risk classification]. Arch Bronconeumol 2003; 39: 101-5
  12. Molinos L, Clemente MG, Miranda B. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. Journal of Infection 2009; 58: 417-24
  13. Global Initiative for Chronic Lung Obstructive Lung Disease (GOLD). Global Strategy for the diagnosis, management and prevention of COPD. www.goldcopd.com (updated 2008).